Buprenorphine - Generic Drug Details

What are the generic sources for buprenorphine and what is the scope of freedom to operate?

Buprenorphine is the generic ingredient in fourteen branded drugs marketed by Amneal, Difgen Pharms, Mylan Tech Viatris, Strides Pharma Intl, Watson Labs Teva, Purdue Pharma Lp, Braeburn, Indivior, Bdsi, Reacx Pharms, Am Regent, Hikma, Hospira, Ph Health, Somerset Theraps Llc, Actavis Elizabeth, Ascent Pharms Inc, Barr, Ethypharm, Pharmobedient, Rhodes Pharms, Rubicon Research, Specgx Llc, Sun Pharm, Alvogen, Dr Reddys Labs Sa, Mylan Technologies, Teva Pharms Usa, Alkem Labs Ltd, Amneal Pharms, Lannett Co Inc, Wes Pharma Inc, and Edenbridge Pharms, and is included in fifty-two NDAs. There are thirty-eight patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Buprenorphine has one hundred and seventy-six patent family members in thirty-six countries.

There are twenty-nine drug master file entries for buprenorphine. Ten suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for buprenorphine

International Patents:	176
US Patents:	38
Tradenames:	14
Applicants:	33
NDAs:	52
Drug Master File Entries:	29
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	20
Clinical Trials:	537
Patent Applications:	4,783
Drug Prices:	Drug price trends for buprenorphine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for buprenorphine
What excipients (inactive ingredients) are in buprenorphine?	buprenorphine excipients list
DailyMed Link:	buprenorphine at DailyMed

See drug prices for buprenorphine

Recent Clinical Trials for buprenorphine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	PHASE3
Braeburn Inc	PHASE4
Atea Pharmaceuticals, Inc.	PHASE1

See all buprenorphine clinical trials

Generic filers with tentative approvals for BUPRENORPHINE

Applicant	Application No.	Strength	Dosage Form
		EQ 8MG BASE;EQ 2MG BASE	FILM;BUCCAL, SUBLINGUAL
		EQ 0.7MG BASE;EQ 0.18MG BASE	TABLET;SUBLINGUAL
		EQ 2.9MG BASE;EQ 0.71MG BASE	TABLET;SUBLINGUAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for buprenorphine

Drug Class	Partial Opioid Agonist
Mechanism of Action	Partial Opioid Agonists

Medical Subject Heading (MeSH) Categories for buprenorphine

Analgesics, Opioid

Narcotic Antagonists

Narcotics

Anatomical Therapeutic Chemical (ATC) Classes for buprenorphine

N02AE	Oripavine derivatives
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

N07BC	Drugs used in opioid dependence
N07B	DRUGS USED IN ADDICTIVE DISORDERS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for BUPRENORPHINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BUTRANS	Transdermal System	buprenorphine	15 mcg/hr	021306	1	2013-12-16
BUTRANS	Transdermal System	buprenorphine	5 mcg/hr 10 mcg/hr 20 mcg/hr	021306	1	2013-06-06

US Patents and Regulatory Information for buprenorphine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Braeburn	BRIXADI	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	210136-002	May 23, 2023		RX	Yes	Yes			Y
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-004	Oct 23, 2015		RX	Yes	No			Y
Ascent Pharms Inc	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	219850-003	Jan 21, 2026	AB	RX	No	No

Expired US Patents for buprenorphine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma Lp	BUTRANS	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	021306-004	Jul 25, 2013
Purdue Pharma Lp	BUTRANS	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	021306-003	Jun 30, 2010
Purdue Pharma Lp	BUTRANS	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	021306-001	Jun 30, 2010

EU/EMA Drug Approvals for buprenorphine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.	Sixmo	buprenorphine	EMEA/H/C/004743Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.	Authorised	no	no	no	2019-06-19
Camurus AB	Buvidal	buprenorphine	EMEA/H/C/004651Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.	Authorised	no	no	no	2018-11-20

International Patents for buprenorphine

Country	Patent Number	Title	Estimated Expiration
Serbia	56820	INJEKTABILNA TEČNA KOMPOZICIJA KOJA SADRŽI BUPRENORFIN (INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE)
China	102008728
Japan	2015522649	オピオイド製剤

Buprenorphine: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is the product and where does it sit in the drug stack?

Buprenorphine is an opioid partial agonist used across three main commercial categories: (1) opioid use disorder (OUD) treatment, (2) pain management, and (3) opioid withdrawal and detox protocols via combination and branded formulations.

Commercially, buprenorphine’s revenue base has been shaped by four forces:

• Formulation-driven channel lock-in: branded sublingual and implantable platforms and payer familiarity.
• Regulatory and guideline alignment in OUD: long-running policy momentum favoring office-based and medication-assisted treatment.
• Generic erosion risk vs. brand stickiness: patent cliffs on certain branded products increase competitive pressure.
• Geographic payer mix: reimbursement depth and restrictions differ by country and by OUD program structure.

Buprenorphine is sold globally in multiple branded and generic formats. In the US, the major OUD franchises include branded sublingual products and long-acting formats (notably injections/implants), alongside numerous generics. In pain, buprenorphine competes with other opioid analgesics and, increasingly, with non-opioid pain approaches.

How does demand move: drivers and constraints

OUD demand drivers

Key demand anchors are persistent and structural:

• Chronic prevalence of OUD sustains prescription continuity and refill demand.
• Medication-assisted treatment (MAT) guideline adherence supports ongoing buprenorphine use as a first-line option in many pathways.
• Provider capacity and access models that enable prescribing at scale support volume growth.

Policy and access efforts in the US have historically supported buprenorphine adoption as part of MAT:

• The US Congress expanded waivered prescriber access via the DATA 2000 framework and subsequent implementation, driving growth in office-based treatment capacity (DATA 2000 enacted as part of the Drug Addiction Treatment Act of 2000). Source: FDA overview of DATA 2000 history and waiver framework. [1]

OUD constraints

• Treatment retention determines economics. Buprenorphine revenue tracks not only new starts but also adherence and duration of treatment.
• Diversion and misuse scrutiny can raise payer and prescriber friction, varying by state/program and product format.
• Competitive substitution between buprenorphine, methadone, and (in some markets) naltrexone-based options changes net share.

Pain demand dynamics

Pain demand is more cyclical and sensitive to:

• Formulary decisions and prior authorization patterns.
• Changing opioid risk frameworks and insurer opioid policies.
• Generic penetration for older buprenorphine pain SKUs in many jurisdictions.

How does the competitive landscape shape market outcomes?

Competitive set

Buprenorphine competes primarily with:

• Methadone (program-based OUD treatment in many settings)
• Naltrexone (oral and long-acting injectables)
• Other opioid partial agonists and mixed mechanisms in select pipelines and regions
• Non-opioid and abuse-deterrent pain products in pain

Market structure: branded platforms vs generics

Commercially, buprenorphine splits into two revenue archetypes:

• Branded OUD products with distinct dosing and program protocols (including long-acting and depot formats where available)
• Generic buprenorphine that competes on price and formulary position

This structure creates a “two-speed” market:

• Branded products often sustain higher net pricing and better payer acceptance in retention and convenience channels.
• Generics drive volume but compress margins and can shift revenue between manufacturers without changing total category demand.

Long-acting segment matters

Long-acting buprenorphine formats are especially consequential for revenue trajectory because they:

• Improve adherence through dosing frequency reduction
• Fit institutional and payer preferences when adherence is a major cost driver

Where payers incentivize adherence and where provider capacity is constrained, long-acting products can outgrow older daily regimens.

What do historical market signals suggest about financial trajectory?

Pricing pressure from generic competition

Buprenorphine faces recurring pricing pressure as branded patents expire and generics expand. For investors and R&D planners, the key implication is not “category growth or decline,” but margin mix:

• Net revenue per patient tends to compress when generics displace branded utilization.
• Volume and market share can stay stable or grow due to ongoing OUD need even as unit revenues weaken.

Utilization patterns and reimbursement

Revenue trajectory depends on:

• Formulary status (preferred tiers vs non-preferred)
• Medicaid coverage and state program design
• Commercial payer prior authorization requirements and step edits
• Patient access programs that reduce cost barriers for OUD medications

US policy context continues to matter because waivered prescribing and MAT support affects uptake and persistence. The FDA’s DATA 2000 framework is part of that access scaffolding. [1]

Distribution and channel economics

Buprenorphine’s market economics are also shaped by:

• Institutional purchasing cycles for long-acting options
• Pharmacy fill patterns for daily regimens
• Switching behavior between daily and long-acting based on adherence, patient preference, and clinician practice

These channel factors can make revenues “lumpy” around product rollouts or new formulary waves.

Where do regulatory and clinical developments land in revenue?

Buprenorphine is an established opioid therapy with decades of clinical usage. Current revenue implications are driven less by fundamental safety re-evaluation and more by:

• Labeling refinement in dosing and indications
• Programmatic access and prescribing frameworks
• Pain policy shifts that influence opioid prescribing volumes
• OUD treatment program funding and coverage

In the US, the MAT and prescribing infrastructure traces to DATA 2000 and related FDA implementation. [1] For global markets, local regulatory access frameworks and payer coverage rules determine the effective addressable market.

How should investors and business teams think about buprenorphine financial trajectory?

A practical model: category, mix, and unit economics

A defensible trajectory framework is:

• Category volume: driven by OUD prevalence, treatment access, and retention
• Mix shift: branded vs generic and daily vs long-acting
• Unit economics: net price and payer rebates driven by formulary position and competition

Buprenorphine typically delivers steadier demand than acute pain opioids, because OUD treatment is ongoing once initiated. Financial upside or downside usually comes from mix (long-acting penetration, branded retention) and pricing (generic erosion, rebate pressure).

What tends to improve revenues (directionally)

• Long-acting adoption that increases adherence and payer acceptance
• Formulary expansion or reduced prior authorization burden
• Program funding that sustains MAT coverage

What tends to reduce revenues (directionally)

• Generic substitution after branded patent expirations
• Payer rebate tightening during competitive entry
• Utilization shifts to competing OUD mechanisms in certain payers/programs

Market outcomes by segment: OUD vs pain

OUD segment

OUD is the primary revenue engine because:

• It is tied to sustained treatment needs
• It has strong policy alignment in MAT frameworks
• It can support long-term prescribing and adherence

Revenue stability is typically higher in OUD than in pain because OUD treatment resembles chronic therapy once patients are in care.

Pain segment

Pain is subject to:

• Greater sensitivity to opioid policy tightening
• Formulary volatility with competing analgesics
• More rapid generic price compression in many markets

As a result, pain can add variability to category revenues even when OUD remains stable.

Time-tested milestone map: what changes trajectory in real time

1) Access and prescribing frameworks

The DATA 2000 waiver program historically increased outpatient treatment capacity and supports OUD initiation and continuity. Source: FDA DATA 2000 overview. [1]

2) Formulation and route innovation

Long-acting delivery systems affect adherence and payer behavior, often changing net share more than overall category demand.

3) Patent and exclusivity events

Branded-to-generic transitions change pricing and margin mix. These events tend to drive step-downs in net revenue for the impacted SKU(s), while total category volume may remain resilient.

Key Takeaways

• Buprenorphine’s revenue trajectory is anchored in OUD demand, with ongoing treatment behavior that supports steadier utilization than acute pain.
• Financial performance is dominated by mix (branded vs generic; daily vs long-acting) and unit economics (net price and rebates under payer competition).
• Regulatory access structures in the US, rooted in DATA 2000, have historically supported outpatient OUD treatment capacity and adoption. [1]
• Near- to mid-term outcomes generally hinge on formulary positioning and long-acting penetration, while longer-term branded revenue faces recurring pressure from generic substitution.

FAQs

1) Is buprenorphine mainly a specialty drug or a pharmacy-driven product?

It is largely pharmacy-driven for daily regimens and program-driven through prescribing networks for OUD, with special channel behavior for long-acting formats where available.

2) What drives buprenorphine category growth: new patients or retention?

Both matter, but financial performance is typically more sensitive to retention and adherence because OUD therapy is chronic once initiated.

3) Does buprenorphine revenue correlate more with OUD prevalence or with pain policy?

Revenue correlations are usually stronger to OUD prevalence and access because OUD treatment is sustained; pain tends to add variability due to shifting opioid prescribing rules and formulary changes.

4) What is the biggest financial risk for buprenorphine in major markets?

Generic substitution and associated net price compression after branded exclusivity periods.

5) Why do long-acting buprenorphine products change financial results?

They can shift mix toward higher net pricing and can improve adherence patterns that influence payer and prescriber preference.

References

[1] U.S. Food and Drug Administration. (n.d.). DATA 2000 (Drug Addiction Treatment Act of 2000) information. FDA. https://www.fda.gov/drugs/addiction-medicine/data-2000-drug-addiction-treatment-act-2000